OCC Applauds FDA for Approval of New Obesity Drug

Today, members of the Obesity Care Continuum (OCC) applauded the Food and Drug Administration’s (FDA) approval of a new obesity drug – Belviq (lorcaserin HCl). Belviq is the first obesity drug to be approved in the past 13 years. To view the full release, click here.

“Take Five to Live Light” Campaign Launches!

The OAC and Orexigen Therapeutics have partnered on a national awareness campaign, called Take Five to Live Light. The campaign aims to educate the more than 93 million Americans affected by the disease of obesity to take five minutes to learn more about: how losing just 5 percent of...

June 2012 – News from the OAC

Obesity Care Continuum (OCC) Exhibits at Weight of the Nation Conference May 7-9, the OAC exhibited with the Obesity Care Continuum (OCC) at the Centers for Disease Control and Prevention’s (CDC) Weight of the Nation Conference, held in Washington, DC. Together, we were able to share the message that...

Page 49 of 52:

© 2018 Obesity Action Coalition 4511 North Himes Avenue • Suite 250 • Tampa, Florida 33614 • (800) 717-3117